UK approval will likely follow that, so realistic availability is 2027 at the earliest and with private prescription first
Clinical trial population adjacent: Obese individuals with higher adiposity, MASLD, T2D/high HbA1c, and/or significant liver fat and metabolic panel improvement goals
While using Semaglutide it is highly recommended that you: Eat a fibrous diet
Refer patients to structured education & weight management programmes Support patients to access structured education and weight management programmes where available
The most common include: Genital yeast infections (more common in women) Urinary tract infections Increased urination or thirst Mild dehydration More serious risks, though less common, include: Ketoacidosis , even in the absence of high blood sugar Acute kidney injury , especially in volume-depleted patients Lower limb amputation risk , though more frequently reported with other SGLT2 inhibitors like canagliflozin To minimize these risks, patients should stay well-hydrated, maintain proper hygiene, and report unusual symptoms such as severe fatigue or nausea